JORGE E CORTES to Alkyl and Aryl Transferases
This is a "connection" page, showing publications JORGE E CORTES has written about Alkyl and Aryl Transferases.
Connection Strength
1.300
-
Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action. Leuk Lymphoma. 2004 Nov; 45(11):2187-95.
Score: 0.236
-
Farnesyl transferase inhibitor R115777 in myelodysplastic syndrome. Curr Hematol Rep. 2004 May; 3(3):157-8.
Score: 0.228
-
Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Clin Lymphoma. 2003 Aug; 4 Suppl 1:S30-5.
Score: 0.217
-
Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood. 2003 Mar 01; 101(5):1692-7.
Score: 0.206
-
Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies. Semin Hematol. 2002 Jul; 39(3 Suppl 2):26-30.
Score: 0.201
-
Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol. 2004 Apr 01; 22(7):1287-92.
Score: 0.057
-
Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood. 2003 Dec 15; 102(13):4527-34.
Score: 0.054
-
Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome. Semin Hematol. 2002 Oct; 39(4 Suppl 3):20-4.
Score: 0.051
-
Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies. Semin Hematol. 2002 Jul; 39(3 Suppl 2):36-8.
Score: 0.050